Health Care • Medical/Dental Instruments
$0.97 ▲ +0.11
(+12.96%)
MKT CAP: $8.8M • VOL: 66.8K
52W L $1 52W H $6
ROARABLE / RQD
D • 49/100
PIOTROSKI
5 / 9
NMTC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $9.1M | $3.5M | $2.0M |
| YoY Revenue Growth % | +163.5% | +76.9% | — |
| Gross Profit | $5.1M | $1.1M | — |
| Gross Margin % | 56.5% | 31.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$4.2M | -$11.9M | -$12.0M |
| Operating Margin % | -46.5% | -80.0% | -80.0% |
| Net Income (GAAP) | -$3.6M | -$12.3M | -$11.9M |
| EBITDA (Normalized) | -$4.2M | -$11.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$2.8M | -$11.0M | -$12.9M |
| Capital Expenditures (CapEx) | $81.7K | $120.2K | — |
| Free Cash Flow (FCF) | -$2.9M | -$11.1M | -$12.9M |
| FCF Margin % | -32.1% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.6M | $1.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.4M | $2.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NMTC.